Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 4,875 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $22.72, for a total value of $110,760.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Anish Patel also recently made the following trade(s):
- On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.03, for a total transaction of $438,025.00.
- On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total value of $90,675.00.
- On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.64, for a total value of $76,245.00.
Enliven Therapeutics Trading Down 0.9 %
ELVN opened at $24.49 on Thursday. The company's 50 day moving average is $17.82 and its 200 day moving average is $14.96. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -11.18 and a beta of 1.05. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $26.00.
Democrats Push to Replace Dollar With Digital Coin, Control Currency.
From Monetary Gold | Ad
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs).
If these plans are implemented, it could mean the end of America as we know it.
This means you must act NOW before it's too late.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. As a group, analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Mizuho initiated coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a "buy" rating and a $34.00 target price for the company.
Check Out Our Latest Report on ELVN
Institutional Trading of Enliven Therapeutics
Several hedge funds have recently bought and sold shares of ELVN. SG Americas Securities LLC raised its position in shares of Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company's stock valued at $187,000 after buying an additional 2,041 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock worth $170,000 after acquiring an additional 1,029 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock valued at $121,000 after purchasing an additional 2,208 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after purchasing an additional 3,189 shares during the period. Finally, AJOVista LLC bought a new stake in shares of Enliven Therapeutics in the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
